Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Dr. Paul Carter, Ph.D.

Bispecific Antibodies as Drugs: Are We There Yet?

Genentech, Inc.

Dr. Matthew Francis, Ph.D.

N-Terminal Protein Modification as a Strategic Way to Create Biomolecular Materials for Diverse Applications

University of California, Berkeley

Dr. Jennifer Cochran, Ph.D.

Next Generation Protein Therapeutics for Treating Cancer

Stanford University

The Past, Present, and Future of ADCs

Ms. Catherine Coombes

The Resolution of the CRISPR USPTO Interference Proceeding

HGF Limited, United Kingdom

7 am 8 am (60 mins)

Main agenda

Coffee & Registration

8 am 8:15 am (15 mins)

Next Generation Protein Therapeutics Summit

Chairperson’s Remarks

8 am 8:15 am (15 mins)

Bioconjugates: From Targets to Therapeutics

Chairperson’s Remarks

  • Thomas Pillow, Ph.D. - Scientist, ADC Team Leader, Genentech, Inc.

8:15 am 8:45 am (30 mins)

Next Generation Protein Therapeutics Summit

Bispecific Antibodies as Drugs: Are We There Yet?

  • Paul Carter, Ph.D. - Staff Scientist and Senior Director, Antibody Engineering, Genentech, Inc.

8:15 am 9:15 am (60 mins)

Bioconjugates: From Targets to Therapeutics

N-Terminal Protein Modification as a Strategic Way to Create Biomolecular Materials for Diverse Applications

Two different chemical strategies will be presented for the single-step modification of the N-terminal positions of proteins and peptides. These strategies are envisioned to be useful for the preparation of many new types of therapeutics, diagnostics, and protein-based materials. The application of these techniques for the efficient preparation of well-defined protein-polymer conjugates will serve as the focus of the presentation.

  • Matthew Francis, Ph.D. - Professor of Chemistry, University of California, Berkeley

8:45 am 9:15 am (30 mins)

Next Generation Protein Therapeutics Summit

Beyond Standard of Care: New and biobetter DARPin® Drugs

  • H. Kaspar Binz, Ph.D. - Vice President and Co-Founder, Molecular Partners AG

9:15 am 9:45 am (30 mins)

Next Generation Protein Therapeutics Summit

Use of Phage Display and Antibody Engineering to Identify and Affinity Optimize a Bacterial Pathogen Specific Antibody for Therapeutic Application

  • Gang Chen, Ph.D. - Senior Research Associate, Donnelly Center for Cellular & Biomedical Research, University of Toronto

8:45 am 9:15 am (30 mins)

Bioconjugates: From Targets to Therapeutics

Site-Specific Conjugation with Expended Genetic Code

Recent technology progress greatly improved the production of therapeutic proteins incorporated with non-natural amino acid in both E. Coli and mammalian cell. This allowed precision protein drug design for protein conjugates which include long-acting proteins and ADCs. Using this robust technology platform, Ambrx created a rich pipeline ranging from early stage discovery to marketed product.

  • Feng Tian, Ph.D. - Chief Scientific Officer, Ambrx Inc.

9:15 am 9:45 am (30 mins)

Bioconjugates: From Targets to Therapeutics

Efficient and Selective Lysine Bioconjugations Using Surfactants

Surfactants are used in lysine-based antibody drug conjugate (ADC) processes in Pfizer to facilitate bioconjugation between the activated calicheamicin derivative (linker payload) and monoclonal antibodies. The choice of surfactant and its concentration in the reaction were shown to have a significant impact on ADC quality attributes.   Data suggested under normal process conditions, surfactants formed micelles solubilizing the hydrophobic calicheamcin derivative in the aqueous reaction media, while minimally impacting the structure of antibodies. The charge of surfactant and the choice of linker payload influenced the lysine sites selected for conjugation. Four major conjugated lysine sites were observed in Mylotarg and Inotuzumab Ozogamicin, as compared to approximate 40 conjugated lysine sites typically observed in conventional lysine-based ADCs.

  • Xi Hu, Ph.D. - Principal Scientist, BioProcess Research & Development, Pfizer Inc.

9:45 am 10:30 am (45 mins)

Main agenda

Networking Refreshment Break in Exhibit/Poster Hall

10:30 am 11 am (30 mins)

Next Generation Protein Therapeutics Summit

The Benefits of Bispecific mAb² Antibodies Targeting EGFR and HGF

  • Francisca Wollerton, Ph.D. - Principal Scientist, Discovery, F-Star Biotechnology Ltd.

11 am 11:30 am (30 mins)

Next Generation Protein Therapeutics Summit

Multi-Specific Antibody Formats for Targeted T-cell Activity

  • Sebastian Meyer, Ph.D. - Vice President, Protein Engineering & CMC, Numab Innovation AG

11:30 am 12 pm (30 mins)

Next Generation Protein Therapeutics Summit

Novel Pairs of Antigen Targets for the Development of Bispecific Antibody Therapeutics

  • Eugene Zhukovsky, Ph.D. - Chief Scientific Officer, Research, Biomunex Pharmaceuticals

10:30 am 11 am (30 mins)

Bioconjugates: From Targets to Therapeutics

Topic TBD

  • Brian McGuinness, Ph.D., MBA - Vice President, Discovery,, Crescendo Biologics

11 am 11:30 am (30 mins)

Bioconjugates: From Targets to Therapeutics

Expressed Protein Ligation as Bioconjugation Platform

Expressed protein ligation uses self-splicing inteins to enable the production of site-specific protein conjugates. While widely used in research settings, less effort has been invested in developing an intein platform suitable for manufacturing of bioconjugate pharmaceuticals. We will present progress in engineering intein constructs to improve the expression and stability of the resulting proteins, with the goal of making commercial use of this technology feasible.

  • Alex Jacobitz, Ph.D. - Postdoctoral Fellow, Synthetic and Hybrid Technologies, Amgen

11:30 am 12 pm (30 mins)

Bioconjugates: From Targets to Therapeutics

Harnessing a Catalytic Lysine Redidue for the Rapid, One-Step Preparation of Homogenous Antibody-Drug Conjugates

Here we present a novel strategy to produce site-specific antibody-drug conjugates (ADCs) using a highly reactive buried lysine residue embedded in a dual variable domain (DVD) format. This approach is mutation free, proceeds rapidly at neutral pH, and can be precisely monitored using a catalytic assay. Highly potent ADCs targeting HER2, CD138, and CD79B were prepared using this approach.

  • Alex Nanna - Graduate Student, Chemistry and Immunology, The Scripps Research Institute

12 pm 12:30 pm (30 mins)

Bioconjugates: From Targets to Therapeutics

Use of Engineered Ligases to Couple Peptides and Peptide-linked Entities to Other Peptides and Proteins

Engineered ligases derived from subtilisin are highly effective in coupling peptides to the N-terminal of other peptides and proteins. Using this chemo-enzymatic peptide synthesis (CEPS) technology, it is possible to couple several peptide fragments together, including those with unusual amino acids, to create synthetic proteins, or to enzymatically ligate such fragments or peptide-linked tags to recombinantly expressed proteins (REPEL).

  • Rodney Lax, Ph.D. - Business Development Consultant, EnzyPep B.V.

12:30 pm 1:40 pm (70 mins)

Main agenda

Luncheon in Exhibit/Poster Hall

1:40 pm 1:45 pm (5 mins)

Next Generation Protein Therapeutics Summit

Chairperson’s Remarks

1:40 pm 1:45 pm (5 mins)

Bioconjugates: From Targets to Therapeutics

Chairperson’s Remarks

  • Jagath Reddy Junutula, Ph.D. - Vice President of Antibody Discovery & Development, Cellerant Therapeutics, Inc

1:45 pm 2:15 pm (30 mins)

Next Generation Protein Therapeutics Summit

Antibody Engineering to Accelerate Antigen Clearance

  • Zenjiro Sampei, Ph.D. - Senior Research Scientist, Biologics Discovery Department, Chugai Pharmaceutical Co., Ltd.

2:15 pm 2:45 pm (30 mins)

Next Generation Protein Therapeutics Summit

A Simple and Robust Method for Quantification and Optimization of Gene Editing Including Differentiation of Gene Disruption and Integration Events and Efficacies

  • Ulrich Brinkmann, Ph.D. - Expert Scientist, Large Molecule Research, Pharma Research & Early Development, Roche Innovation Center Munich

1:45 pm 2:15 pm (30 mins)

Bioconjugates: From Targets to Therapeutics

Conjugation of Targeting Ligands to Functionalized Polymeric Nanoparticles

  • Roger Pak, Ph.D. - Associate Research Fellow, BioTherapeutics Pharmaceutical R&D, Pfizer

2:15 pm 2:45 pm (30 mins)

Bioconjugates: From Targets to Therapeutics

Linker Optimization Leads to Better ADCs in Terms of In Vitro and In Vivo Outcome

  • Ying Sun, Ph.D. - Associate Director, R&D, Ambrx Inc.

2:45 pm 3:30 pm (45 mins)

Main agenda

Networking Refreshment Break in Exhibit/Poster Hall

3:30 pm 4 pm (30 mins)

Main agenda

Next Generation Protein Therapeutics for Treating Cancer

We use natural ligands and receptors as scaffolds for protein engineering to leverage their inherent biophysical and biochemical properties. I will present our recent data on therapeutic candidates engineered to possess high affinity and unique specificities for applications in oncology.

  • Jennifer Cochran, Ph.D. - Associate Professor, Bioengineering & Chemical Engineering, Stanford University

4 pm 4:30 pm (30 mins)

Main agenda

The Past, Present, and Future of ADCs

4:30 pm 5 pm (30 mins)

Main agenda

The Resolution of the CRISPR USPTO Interference Proceeding

An up to date overview of the patent landscape of the foundational CRISPR/Cas9 IP in US, Europe and further afield following the recent ruling in the US patent interference, focusing on some of the key issues and lessons that can be learnt from these as well as the commercial implication. This talk will also provide tips on how both scientific accolades and patents can be achieved in a fast evolving field.

  • Catherine Coombes - Senior Patent Attorney, HGF Limited, United Kingdom

5 pm 6:30 pm (90 mins)

Main agenda

Cocktail Reception in the Exposition Hall